As a service provider in novel immunotherapy development, Creative Biolabs is dedicated to offering a wide spectrum of TAC in vitro analysis assay services to illustrate TAC bioactivity and mechanism of action. These assays mainly focus on immune cell activation, proliferation and killing analysis, and tumor-infiltrating lymphocyte monitoring.
We used human primary cells and their derived subpopulations to establish baseline models to provide a comprehensive analysis of the target efficacy, off-target killing, and potential cytotoxicity of TAC-T cell therapy. We have been expanding the scope of our evaluation beyond conventional cell types, to include some rare cell therapy targets.
Regardless of the stage of development, TAC-T and its cellular therapies need to be evaluated for safety and efficacy. Normally, the antitumor efficacy of TAC is mainly affected by its activation, proliferation, inhibition, and depletion processes. As a result, we have generated a series of assays for providing a comprehensive analysis of TAC cell therapy. Our platform mainly evaluates the following in vitro experimental indicators for detection:
Recently, we offer single or multiplex cytokine level analysis for your TAC-T cells using flow cytometry. Meanwhile, we also provide comprehensive cell content analysis for assessment of non-tumor cell targeting of TAC-T therapy. Also, the expression levels of several memory markers, including CD45RA, CCR7, and CD28, are detected for further identifying the function and the activation degree of TAC-T cells.
Up to now, we have established a novel method of T cell activation assay to match your particular project, such as the detection of activation markers on the cell surface, the clonal expansion test of T cells, as well as TCR/CD3 effector cells detection assay. Moreover, the Durability testing service of TAC-T cell tumor killing is demonstrated by tumor cell repeated stimulation assay, in which tumor cells were added at sites to observe the clearance of tumor cells by TAC T cells. In general, TAC-T cells are co-cultured in vitro with positive and negative target expression cells, and the bioactivity, specificity, and efficacy of TAC-T cells will be reflected by statistical analysis of the ratio of activated T cells to dead cells. This assay includes multiple target ratios and time points, which allows for a more intuitive determination of the lower and upper limits of TAC-T cell therapy.
Fig.1 In Vitro TAC-T Cell Therapy Testing Assays.
In addition, we also provide a variety of efficient and innovative tests and reagents for the detection of cell viability and cytotoxicity. Various kits can be selected to detect cell viability or toxicity in cell culture medium based on the luminescence reading. Meanwhile, many detection systems can be superimposed with apoptosis and other vitality detection reagents to determine the mechanism of cell death and to sensitively compare the data between holes, plates, and days.
BCMA TAC T cell cytotoxic activity in vitro.
The purity and phenotype of transduced human BCMA-TAC T cells were determined by ELISA. Dose-response cytotoxicity curves were drawn using BCMA-TAC T cells and target cells with an E: T ratio of 10:1.
Fig.2 The Detection Example Result of BCMA-TAC T Cell.
BCMA-TAC and CD19-TAC expression testing by flow cytometry.
Fig.3 Flow Cytometry Analysis of BCMA-TAC and CD19-TAC Expression.
Creative Biolabs offers a series of TAC in vitro assays which are part of our one-stop solution TAC-engineered T cell therapy development services. Experienced teams of scientists, researchers, and technicians, we provide fast turnaround, high-quality data at competitive prices for worldwide customers. Our clients have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
For Research Use Only
